`_______________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`SAMSUNG BIOEPIS CO., LTD.
`Petitioner,
`
`v.
`REGENERON PHARMACEUTICALS, INC.
`Patent Owner.
`
`Patent No. 11,253,572
`
`_______________
`Inter Partes Review No. IPR2023-00884
`____________________________________________________________
`
`DECLARATION OF KIRA A. DAVIS IN SUPPORT OF
`MOTION FOR ADMISSION PRO HAC VICE
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2060 Page 1
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`IPR2023-00884
`
`I, Kira A. Davis, declare as follows:
`
`1.
`
`I am an attorney licensed to practice law in the states of New York
`
`and California and am admitted to practice before the United States Court of
`
`Appeals for the Federal Circuit. I am also admitted to practice before the United
`
`States Court of Appeals for the Second Circuit, the United States Court of Appeals
`
`for the Sixth Circuit, and the United States District Courts for the Southern District
`
`of New York, the Eastern District of New York, the Northern District of
`
`California, and the Central District of California.
`
`2.
`
`I am a member in good standing in all jurisdictions where I have been
`
`admitted to practice.
`
`3.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`4.
`
`I have never had an application denied for admission before any court
`
`or administrative body.
`
`5.
`
`I have never had any sanctions or contempt citations imposed by any
`
`court or administrative body.
`
`6.
`
`I have read and agree to comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in 37 C.F.R. part 42.
`
`7.
`
`I affirm my agreement before the USPTO to be subject to the USPTO
`
`Rules of Professional Conduct 37 C.F.R. §§ 11.101 et seq. and disciplinary
`
`
`
`
`1
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2060 Page 2
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`IPR2023-00884
`
`jurisdiction under 37 C.F.R. § 11.19(a).
`
`8.
`
`I have applied to appear pro hac vice in the following proceedings
`
`before the USPTO in the last three (3) years:
`
`a. Celltrion Inc. v. Regeneron Pharmaceuticals Inc., IPR2023-00462
`
`(pro hac vice granted).
`
`b. Samsung Bioepis Co., LTD v. Regeneron Pharmaceuticals Inc.,
`
`IPR2023-00739 (pro hac vice pending).
`
`9.
`
`I have been a partner at the law firm of Morrison & Foerster LLP
`
`since I joined the firm on January 1, 2023. I was previously a partner at the law
`
`firm of Durie Tangri LLP, from July 1, 2020 through December 31, 2022. Prior to
`
`that I was employed at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison
`
`LLP. I have worked on patent litigation matters, and particularly, patent litigation
`
`matters relating to biotechnology, for approximately 12 years. Over my twelve
`
`years working on patent litigation matters, I have handled many patent cases
`
`relating to methods of treatment using biologic therapeutics, including fusion
`
`proteins and antibodies.
`
`10.
`
`I am familiar with the subject matter at issue in this proceeding. I
`
`have been engaged by the Patent Owner to represent the Patent Owner before the
`
`Board in this proceeding. I have undertaken the study of inter alia the ’572 Patent,
`
`the Petition for Inter Partes Review, and the art cited in the Petition. I am also
`
`
`
`
`2
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2060 Page 3
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`IPR2023-00884
`
`familiar with the co-pending litigations identified by the Petitioner in the Petition
`
`for Inter Partes Review, Paper 2 at 6. I have represented Patent Owner in patent
`
`matters relating to Eylea® since September 2022. I have acquired a substantial
`
`understanding of the underlying legal and technological issues at stake in these
`
`proceedings.
`
`
`
`
`
`I hereby declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements are made with the knowledge that willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under Section 1001 of Title 18 of the United States Code and that such willful false
`
`statements may jeopardize the validity of U.S. Patent No. 11,253,572.
`
`
`
`Dated: December 20, 2023
`
`
`
`
`
`By: /Kira A. Davis/
`Kira A. Davis
`MORRISON & FOERSTER LLP
`707 Wilshire Boulevard, Suite 6000
`Los Angeles, CA 90017
`Tel: (213) 892-5654
`
`
`
`
`3
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2060 Page 4
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
